Suchergebnisse - "Luo, Dong-Hua"

PubPharm (126)

1

Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2024

von Yu-Chen | Luo, M. | Liu, R. | +14

2

Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area : a phase II, single-arm trial

enthalten in: The Lancet regional health. Western Pacific | 2023

von Luo, D. | Li, X. | Guo, S. | +14

3

Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma : a multicenter study

enthalten in: BMC medicine | 2023

von Liu, T. | Dong, D. | Zhao, X. | +30

CommentIn: BMC Med. 2023 Nov 28;21(1):465. - PMID 38017483

4

Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study

enthalten in: BMC medicine | 2023

von Liu, T. | Dong, D. | Zhao, X. | +30

5

Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma : A single-arm, phase 2 trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Guo, S. | Yang, J. | Sun, X. | +20

6

A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Liang, Y. | Chen, Q. | Xu, J. | +18

7

The map of bone metastasis in nasopharyngeal carcinoma : A real-world study

enthalten in: Cancer medicine | 2023

von Luo, D. | Li, J. | Guo, W. | +8

8

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma : a single-arm, phase 2 trial

enthalten in: Nature communications | 2023

von Yuan, L. | Jia, G. | Lv, X. | +17

9

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma : a multicentre, open-label, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Liu, L. | Liu, H. | Huang, Y. | +28

CommentIn: Lancet Oncol. 2023 Jul;24(7):713-715. - PMID 37290469

10

Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis : a comprehensive nomogram model

enthalten in: European radiology | 2023

von Sun, X. | Xiao, Z. | Liu, S. | +4

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]